{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:09:29Z","timestamp":1788318569395,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fascioliasis occurs on all inhabited continents. It is caused by Fasciola hepatica and Fasciola gigantica, trematode parasites with complex life cycles, and primarily affects domestic livestock. Humans become infected after ingestion of contaminated food (typically wild aquatic vegetables) or water. Fascioliasis may be difficult to diagnose as many symptoms are non-specific (e.g. fever, abdominal pain and anorexia). Treatment options are limited, with older effective therapies such as emetine and bithionol no longer used due to safety issues and unavailability, and most common anthelminthics having poor efficacy. Clinical trials conducted over a 25-year period, together with numerous case reports, demonstrated that triclabendazole has high efficacy in the treatment of human fascioliasis in adults and children and in all stages and forms of infection. Triclabendazole was approved for human use in Egypt in 1997 and in France in 2002 and a donation program for the treatment of fascioliasis in endemic countries was subsequently established by the manufacturer and administered by the World Health Organization. Here the published data on triclabendazole in the treatment of human fascioliasis are reviewed, with a focus on more recent data, in light of the 2019 US Food and Drug Administration approval of the drug for use in human infections.<\/jats:p>","DOI":"10.1093\/trstmh\/trz093","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T11:26:45Z","timestamp":1565695605000},"page":"797-804","source":"Crossref","is-referenced-by-count":116,"title":["Triclabendazole in the treatment of human fascioliasis: a review"],"prefix":"10.1093","volume":"113","author":[{"given":"Preetam","family":"Gandhi","sequence":"first","affiliation":[{"name":"Global Health Development Unit, Forum 3, Novartis Pharma AG, Novartis Campus, Lichtstrasse, 4002 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther K","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Global Health Development Unit, Forum 3, Novartis Pharma AG, Novartis Campus, Lichtstrasse, 4002 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, One Health Plaza-315\/5320 B, East Hanover NJ, 07936 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Samantray","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd, Salarpuria-Sattva Knowledge City, Inorbit Mall Rd, Silpa Gram Craft Village, HITEC City, Hyderabad, Telangana 500081, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Kumar","family":"Venishetty","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd, Salarpuria-Sattva Knowledge City, Inorbit Mall Rd, Silpa Gram Craft Village, HITEC City, Hyderabad, Telangana 500081, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hughes","sequence":"additional","affiliation":[{"name":"Global Health Development Unit, Forum 3, Novartis Pharma AG, Novartis Campus, Lichtstrasse, 4002 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"2019121207372597300_ref1","author":"US Food and Drug Administration"},{"issue":"13","key":"2019121207372597300_ref2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1017\/S0031182018000914","article-title":"Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures","volume":"145","author":"Mas-Coma","year":"2018","journal-title":"Parasitology."},{"issue":"14","key":"2019121207372597300_ref3","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1017\/S0031182014000869","article-title":"Diagnosis of human fascioliasis by stool and blood techniques: update for the present global scenario","volume":"141","author":"Mas-Coma","year":"2014","journal-title":"Parasitology."},{"key":"2019121207372597300_ref4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-308X(09)69002-3","article-title":"Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control","volume":"69","author":"Mas-Coma","year":"2009","journal-title":"Adv Parasitol."},{"issue":"3","key":"2019121207372597300_ref5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1473-3099(11)70294-8","article-title":"Global burden of human food borne trematodiasis: a systematic review and meta analysis","volume":"12","author":"Furst","year":"2012","journal-title":"Lancet Infect Dis."},{"key":"2019121207372597300_ref6","volume-title":"Neglected tropical diseases","author":"World Health Organization"},{"key":"2019121207372597300_ref7","volume-title":"Tropical disease priority review vouchers. Guidance for industry","author":"Center for Drug Evaluation and Research\/Center for Biologics Evaluation and Research","year":"2016"},{"issue":"3","key":"2019121207372597300_ref8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4269\/ajtmh.2012.11-0448","article-title":"Burden of Fasciola hepatica infection among children from Paucartambo in Cusco, Peru","volume":"86","author":"Lopez","year":"2012","journal-title":"Am J Trop Med Hyg."},{"key":"2019121207372597300_ref9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-800099-1.00002-8","article-title":"Neurological and ocular fascioliasis in humans","volume":"84","author":"Mas-Coma","year":"2014","journal-title":"Adv Parasitol."},{"issue":"5\u20136","key":"2019121207372597300_ref10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2000.63.264","article-title":"The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection","volume":"63","author":"Mill\u00e1n","year":"2000","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"2019121207372597300_ref11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00005792-199501000-00002","article-title":"Fascioliasis in developed countries: a review of classic and aberrant forms of the disease","volume":"74","author":"Arjona","year":"1995","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"2019121207372597300_ref12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/QCO.0b013e32830f9818","article-title":"Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis","volume":"21","author":"Marcos","year":"2008","journal-title":"Curr Opin Infect Dis."},{"issue":"44","key":"2019121207372597300_ref13","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.3748\/wjg.v17.i44.4899","article-title":"Clinical presentation and management of Fasciola hepatica infection: single-center experience","volume":"17","author":"Kaya","year":"2011","journal-title":"World J Gastroenterol."},{"issue":"12","key":"2019121207372597300_ref14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1517\/13543784.14.12.1513","article-title":"Triclabendazole for the treatment of fascioliasis and paragonimiasis","volume":"14","author":"Keiser","year":"2005","journal-title":"Expert Opin Investig Drugs."},{"issue":"1","key":"2019121207372597300_ref15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3347\/kjp.2011.49.1.65","article-title":"A case of biliary Fascioliasis by Fasciola gigantica in Turkey","volume":"49","author":"Goral","year":"2011","journal-title":"Korean J Parasitol."},{"key":"2019121207372597300_ref16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/1756-0500-5-691","article-title":"Sporadic incidence of fascioliasis detected during hepatobiliary procedures: a study of 18 patients from Sulaimaniyah governorate","volume":"5","author":"Hawramy","year":"2012","journal-title":"BMC Res Notes."},{"key":"2019121207372597300_ref17","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-008306","article-title":"Unusual case of a lung abscess","volume":"2013","author":"Musa","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2019121207372597300_ref18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/QCO.0b013e3283567b7e","article-title":"New developments in epidemiology, diagnosis, and treatment of fascioliasis","volume":"25","author":"Cabada","year":"2012","journal-title":"Curr Opin Infect Dis."},{"issue":"6","key":"2019121207372597300_ref19","first-page":"397","article-title":"A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni","volume":"14","author":"Katz","year":"1972","journal-title":"Rev Inst Med Trop Sao Paulo."},{"issue":"2","key":"2019121207372597300_ref20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4269\/ajtmh.2008.78.222","article-title":"Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis","volume":"78","author":"Marcos","year":"2008","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"2019121207372597300_ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1469-0691.2011.03575.x","article-title":"Acute fascioliasis\u2014clinical and epidemiological features of four patients in Chile","volume":"18","author":"Fica","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"2019121207372597300_ref22","first-page":"519","volume-title":"Drugs for helminths","author":"McCarthy","year":"2015","edition":"8th"},{"issue":"2","key":"2019121207372597300_ref23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1017\/S0022149X09321173","article-title":"Triclabendazole progress report, 2005\u20132009: an advancement of learning?","volume":"83","author":"Fairweather","year":"2009","journal-title":"J Helminthol."},{"issue":"6","key":"2019121207372597300_ref24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.pt.2016.03.002","article-title":"Current threat of triclabendazole resistance in Fasciola hepatica","volume":"32","author":"Kelley","year":"2016","journal-title":"Trends Parasitol."},{"issue":"5","key":"2019121207372597300_ref25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1017\/S0031182000077428","article-title":"The effect of the sulphoxide metabolite of triclabendazole (Fasinex\u00ae) on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica","volume":"108","author":"Stitt","year":"1994","journal-title":"Parasitology."},{"issue":"1","key":"2019121207372597300_ref26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2885.1987.tb00078.x","article-title":"The kinetics of triclabendazole disposition in sheep","volume":"10","author":"Hennessy","year":"1987","journal-title":"J Vet Pharmacol Ther."},{"issue":"6","key":"2019121207372597300_ref27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-2125.1998.00725.x","article-title":"Effect of food on the bioavailability of triclabendazole in patients with fascioliasis","volume":"45","author":"Lecaillon","year":"1998","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"2019121207372597300_ref28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11096-006-9069-8","article-title":"Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects","volume":"29","author":"el-Tantawy","year":"2007","journal-title":"Pharm World Sci."},{"issue":"2","key":"2019121207372597300_ref29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2036.2003.01419.x","article-title":"Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru","volume":"17","author":"Favennec","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2019121207372597300_ref30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4269\/ajtmh.2008.78.388","article-title":"A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam","volume":"78","author":"Hien","year":"2008","journal-title":"Am J Trop Med Hyg."},{"issue":"9","key":"2019121207372597300_ref31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001285","article-title":"Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials","volume":"5","author":"Keiser","year":"2011","journal-title":"PLoS Negl Trop Dis."},{"key":"2019121207372597300_ref32","first-page":"325","volume-title":"Triclabendazole for fascioliasis: efficacy and tolerability of a single dose treatment","author":"Laburte","year":"1998"},{"issue":"4","key":"2019121207372597300_ref33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0037-8682-0148-2015","article-title":"Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children","volume":"48","author":"Maco","year":"2015","journal-title":"Rev Soc Bras Med Trop."},{"issue":"8","key":"2019121207372597300_ref34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001720","article-title":"Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano","volume":"6","author":"Villegas","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"issue":"5","key":"2019121207372597300_ref35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.26719\/1999.5.5.888","article-title":"Triclabendazole in the treatment of human fascioliasis: a community-based study","volume":"5","author":"el-Morshedy","year":"1999","journal-title":"East Mediterr Health J."},{"issue":"11","key":"2019121207372597300_ref36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1440-1681.2004.04093.x","article-title":"Randomized trial of a single, double and triple dose of 10 mg\/kg of a human formulation of triclabendazole in patients with fascioliasis","volume":"31","author":"Talaie","year":"2004","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"4","key":"2019121207372597300_ref37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1017\/S095026880600728X","article-title":"Endemic human fasciolosis in the Bolivian Altiplano","volume":"135","author":"Parkinson","year":"2007","journal-title":"Epidemiol Infect."},{"key":"2019121207372597300_ref38","volume-title":"Neglected tropical diseases","author":"World Health Organization"},{"issue":"6","key":"2019121207372597300_ref39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4269\/ajtmh.1995.52.532","article-title":"Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response","volume":"52","author":"Apt","year":"1995","journal-title":"Am J Trop Med Hyg."},{"issue":"3","key":"2019121207372597300_ref40","first-page":"255","article-title":"Human infection by Fasciola hepatica in Venezuela: report of a geriatric case","volume":"44","author":"Incani","year":"2003","journal-title":"Invest Clin."},{"issue":"8","key":"2019121207372597300_ref41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.trstmh.2005.03.004","article-title":"Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt","volume":"99","author":"Curtale","year":"2005","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"1","key":"2019121207372597300_ref42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medmal.2005.10.005","article-title":"Eight cases of fascioliasis: clinical and microbiological features","volume":"36","author":"Dauchy","year":"2006","journal-title":"Med Mal Infect."},{"issue":"3","key":"2019121207372597300_ref43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.trstmh.2008.10.024","article-title":"Cervical tumor caused by the sexually mature stage of Fasciola hepatica","volume":"103","author":"Marcos","year":"2009","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"3","key":"2019121207372597300_ref44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4318\/tjg.2011.0226","article-title":"A case of ectopic intraabdominal fascioliasis presented with acute abdomen","volume":"22","author":"Tanir","year":"2011","journal-title":"Turk J Gastroenterol."},{"issue":"8","key":"2019121207372597300_ref45","article-title":"An outbreak of human fascioliasis gigantica in southwest China","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One."},{"issue":"2","key":"2019121207372597300_ref46","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0022-3859.97180","article-title":"Cases of human fascioliasis in India: tip of the iceberg","volume":"58","author":"Ramachandran","year":"2012","journal-title":"J Postgrad Med."},{"issue":"6","key":"2019121207372597300_ref47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3201\/eid1806.120302","article-title":"Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands","volume":"18","author":"Winkelhagen","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"2019121207372597300_ref48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004361","article-title":"Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series","volume":"10","author":"Cabada","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"issue":"10","key":"2019121207372597300_ref49","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.4067\/S0034-98872014001000014","article-title":"Fascioliasis hep\u00e1tica humana: resistencia al tratamiento con triclabendazol","volume":"142","author":"Gil","year":"2014","journal-title":"Rev Med Chile."},{"key":"2019121207372597300_ref50","author":"World Health Organization"},{"key":"2019121207372597300_ref51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.3.5721.502","article-title":"Fascioliasis\u2014a large outbreak","volume":"3","author":"Hardman","year":"1970","journal-title":"Br Med J."},{"issue":"2","key":"2019121207372597300_ref52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0035-9203(88)90452-X","article-title":"Treatment of acute toxaemic fascioliasis","volume":"82","author":"Farid","year":"1988","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"5","key":"2019121207372597300_ref53","first-page":"333","article-title":"Human fascioliasis in Egypt: effect of infection and efficacy of bithionol treatment","volume":"94","author":"Bassiouny","year":"1991","journal-title":"J Trop Med Hyg."},{"issue":"1","key":"2019121207372597300_ref54","first-page":"40","article-title":"Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients","volume":"17","author":"Yazgan-Aksoy","year":"2006","journal-title":"Turk J Gastroenterol."},{"issue":"10","key":"2019121207372597300_ref55","first-page":"127","article-title":"The effect of metronidazole in treating human fascioliasis","volume":"9","author":"Mansour-Ghanaei","year":"2003","journal-title":"Med Sci Monit."},{"issue":"1","key":"2019121207372597300_ref56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0035-9203(98)90974-9","article-title":"Successful treatment of human fascioliasis with nitazoxanide","volume":"92","author":"Rossignol","year":"1998","journal-title":"Trans R Soc Trop Med Hyg."},{"issue":"11","key":"2019121207372597300_ref57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002553","article-title":"Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide","volume":"7","author":"Zumaquero-R\u00edos","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"key":"2019121207372597300_ref58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12879-015-1326-9","article-title":"Diagnosis of human fascioliasis in Arusha region, northern Tanzania by microscopy and clinical manifestations in patients","volume":"15","author":"Lukambagire","year":"2015","journal-title":"BMC Infect Dis."},{"key":"2019121207372597300_ref59","author":"Pan American Health Organization"},{"key":"2019121207372597300_ref60","author":"Centers for Disease Control and Prevention"},{"key":"2019121207372597300_ref61","volume-title":"Access to Medicine Foundation","year":"2016"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/113\/12\/797\/31501693\/trz093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/113\/12\/797\/31501693\/trz093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T15:35:20Z","timestamp":1664120120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/113\/12\/797\/5602280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,10,22]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trz093","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,10,22]]}}}